Core Insights - Avantor reported mixed Q2 2025 results, with GAAP revenue exceeding analyst expectations but non-GAAP EPS falling short [1][5] - The company faces ongoing operational and competitive pressures, alongside a pending CEO transition [1][9] Financial Performance - GAAP revenue for Q2 2025 was $1,683.4 million, slightly above the estimate of $1,674.6 million, but down 1.1% year-over-year [2][5] - Non-GAAP EPS was $0.24, missing the consensus estimate of $0.25 and reflecting a 4% decline from Q2 2024 [2][5] - Adjusted EBITDA was $279.8 million, down 8.4% from $305.6 million in Q2 2024 [2][5] - Free cash flow decreased by 46.7% to $125.4 million compared to $235.3 million in Q2 2024 [2][7] - Net income (GAAP) fell to $64.7 million from $92.9 million in Q2 2024 [7] Segment Performance - The Laboratory Solutions segment experienced a 3% drop in net sales, with an organic decline of 1.0% [6] - The Bioscience Production segment achieved a 3% increase in reported sales, but its adjusted operating margin declined due to maintenance and regulatory challenges [6] Strategic Focus - Avantor's business relies on a diverse product mix, global presence, strong customer relationships, and commitment to ESG standards [4] - The company is targeting $400 million in run-rate cost savings by the end of 2027 as part of its multiyear transformation plan [7] Future Outlook - No updated financial guidance was provided for the remainder of fiscal 2025, but management emphasized the importance of recurring revenue contracts and efficiency programs [9][10] - Key areas to monitor include revenue trends in Laboratory Solutions, margin developments, and progress in cost-saving initiatives [10]

Core Insights - Avantor, Inc. reported second-quarter 2025 adjusted earnings per share (EPS) of 24 cents, a decrease of 4% year-over-year, and missed the Zacks Consensus Estimate by 4% [1][7] - The company's revenues for the quarter were $1.68 billion, down 1.1% year-over-year, but exceeded the Zacks Consensus Estimate by 0.4% [2][7] - The company has updated its 2025 guidance, projecting adjusted EPS to be in the range of 94 cents to 98 cents, down from the previous guidance of $1.02 to $1.10 [16] Revenue and Earnings Analysis - Revenues grossed $1.68 billion, reflecting a 1.1% decline year-over-year, with organic sales remaining flat [2][7] - GAAP EPS for the quarter was 9 cents, down 35.7% year-over-year [1][7] - The gross profit declined 4.7% year-over-year to $554.1 million, with a gross margin of 32.9%, down 120 basis points [12] Segment Performance - The Laboratory Solutions segment reported net sales of $1.12 billion, a decrease of 2.9% year-over-year, with organic sales down 1% [4] - Bioscience Production's net sales were $561.3 million, reflecting a 2.6% increase, with organic sales up 1.5% year-over-year [9] - The company faced challenges in bioprocessing, which was flat year-over-year due to maintenance and disruptions from key customers [10] Market Position and Competitive Landscape - Avantor's shares have declined 15.5% in the recent trading period and 46.1% year-to-date, compared to an 8.5% decline in the industry [3] - Management noted ongoing competitive intensity, particularly among large biopharma accounts, and has taken strategic pricing actions to protect market share [5][18] Financial Position - At the end of Q2 2025, Avantor had cash and cash equivalents of $449.4 million, up from $315.7 million at the end of Q1 2025, while total debt increased to $4.24 billion [13] - Cumulative net cash provided by operating activities was $263.7 million, down from $422.7 million a year ago [13] Strategic Initiatives - The company is focusing on digital tools to enhance customer experience, including the launch of Avantor Navigator, an AI-powered application [18][19] - Avantor is also implementing a cost transformation program aimed at achieving $400 million in run-rate savings by the end of 2027 [20] - Efforts are underway to optimize supply chain performance and improve operational efficiency, particularly in the Bioscience Production segment [21]

Core Viewpoint - Avantor Inc. reported worse-than-expected second-quarter 2025 adjusted EPS, leading to a decline in stock price, with shares nearing their 52-week low [1]. Financial Performance - The company reported adjusted EPS of 24 cents, slightly below the consensus estimate of 25 cents [1]. - Sales for the quarter were $1.68 billion, nearly in line with the consensus of $1.675 billion, but fell 1% compared to the second quarter of 2024 [1][2]. - Net income decreased to $64.7 million from $92.9 million a year ago, while adjusted net income was $161.2 million compared to $168 million [5]. - Adjusted EBITDA was $279.8 million, down from $305.6 million, with a margin of 16.6% [5]. - Adjusted operating income fell from $277.2 million to $252.2 million, with a margin of 15.0% [6]. Segment Performance - Laboratory Solutions sales were $1.12 billion, a reported decrease of 3%, with a 1% organic decline [2]. - Bioscience Production sales were $561.3 million, also a reported decrease of 3%, but showed a 2% increase on an organic basis [3]. - The bioprocessing performance did not meet expectations due to planned maintenance at a manufacturing facility, despite strong demand for the monoclonal antibody platform [4]. Strategic Developments - The company announced significant actions to accelerate growth and enhance its cost structure, targeting $400 million in gross run-rate savings by the end of 2027 [6]. - A five-year contract extension with BIO Business Solutions was executed, positioning the company to benefit from future funding levels in the biotech industry [7]. Market Position - Avantor stock trades at approximately 10.8 times the 2025 EBITDA estimate, compared to peers at 15.4 times and its own average of 15.9 times as a public company [8]. - The company's growth and margin profile are considered below peer levels, justifying the current discount to peers [8].

Core Insights - Avantor, Inc. reported revenue of $1.68 billion for the quarter ended June 2025, reflecting a decrease of 1.1% year-over-year, with EPS at $0.24 compared to $0.25 in the same quarter last year [1] - The reported revenue met the Zacks Consensus Estimate, showing a surprise of +0.38%, while the EPS fell short of expectations by 4% [1] Revenue Breakdown - Bioscience Production revenue was $561.3 million, slightly below the estimated $568.43 million, marking a year-over-year increase of +2.6% [4] - Laboratory Solutions revenue reached $1.12 billion, exceeding the average estimate of $1.11 billion, but represented a year-over-year decline of -2.9% [4] Operating Income Analysis - Adjusted Operating Income for Laboratory Solutions was reported at $133.3 million, below the average estimate of $144.2 million [4] - Adjusted Operating Income for Corporate was -$20.8 million, worse than the average estimate of -$17.99 million [4] - Adjusted Operating Income for Bioscience Production was $139.7 million, slightly above the estimated $134.75 million [4] Stock Performance - Avantor's shares have returned -3.2% over the past month, contrasting with the Zacks S&P 500 composite's +2.3% change [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance relative to the broader market in the near term [3]

Financial Data and Key Metrics Changes - The company reported second quarter revenue of $1.68 billion, flat year-over-year on an organic basis [19] - Adjusted EBITDA margin contracted to 16.6%, with adjusted EPS for the quarter at $0.24, reflecting a year-over-year decline of $0.01 [8][21] - Free cash flow was $125 million, with adjusted conversion at 100% [8][21] - The company remains on track with its cost transformation program, expecting $400 million in run rate savings by 2027 [8] Business Line Data and Key Metrics Changes - Laboratory Solutions, which constitutes roughly two-thirds of the business, saw organic revenue growth in line with expectations, increasing sequentially compared to Q1 but finishing modestly down year-over-year [8][22] - Bioscience production revenue was $561 million, up 2% organically year-over-year and up 7% sequentially, with bioprocessing performance flat year-over-year due to customer headwinds [24][26] Market Data and Key Metrics Changes - The European business in Laboratory Solutions was nearly flat, outperforming The Americas and Asia, which faced greater policy headwinds [22] - The company experienced significant contract extensions with several top global pharma accounts, expected to yield over $100 million in share gains once fully commercialized [12] Company Strategy and Development Direction - The company is focused on executing strategic initiatives to drive growth, improve operating efficiency, and deliver long-term value despite ongoing challenges in the operating environment [7][32] - The leadership transition to Emanuel Ligner as the new CEO is expected to bring additional expertise, particularly in bioprocessing [6][104] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing competitive intensity and the need to protect and grow market share while preserving profitability [13][32] - The full-year organic revenue growth expectation has been reduced to negative 2% to flat, reflecting current trends and headwinds [27][28] Other Important Information - The company is implementing several digital initiatives to enhance customer experience, including the Avantor Navigator AI application and a new digital buying experience platform [11] - Adjusted EBITDA margin expectations have been updated to between 16.5% and 17% for the full year [30] Q&A Session Summary Question: Guidance for third quarter organic growth - Management indicated that the guidance reflects consistency in performance across segments, with some seasonality and timing issues impacting bioprocessing [36][37] Question: Impact of pricing and mix on margins - The decline in EBITDA margins was attributed primarily to pricing actions and mix, particularly in the lab business [38][39] Question: Long-term growth outlook for bioprocessing - Management remains confident in the long-term growth potential of bioprocessing, despite recent headwinds, citing strong demand for the monoclonal antibody platform [44][45] Question: Free cash flow reduction and contract dynamics - The reduction in free cash flow guidance is linked to significant contract extensions that involve upfront rebate payments [86][87] Question: Customer-specific challenges in bioprocessing - Management acknowledged unexpected customer headwinds impacting bioprocessing performance, but emphasized the overall strength of the platform and ongoing recovery in the end market [100][101]

[Glossary](index=4&type=section&id=Glossary) Provides definitions for key terms used throughout the financial report [Cautionary factors regarding forward-looking statements](index=5&type=section&id=Cautionary%20factors%20regarding%20forward-looking%20statements) Highlights inherent risks and uncertainties associated with forward-looking statements in the report - The report contains forward-looking statements subject to risks, uncertainties, and assumptions, which are not guarantees of performance[7](index=7&type=chunk)[8](index=8&type=chunk) - Key factors that could affect future results include disruptions, competition, ability to implement strategies, changing industry trends, adverse spending trends, dependence on limited sources, integration of acquired businesses, product quality, customer and distributor relationships, and regulatory changes[9](index=9&type=chunk)[10](index=10&type=chunk) [PART I — FINANCIAL INFORMATION](index=8&type=section&id=PART%20I%20%E2%80%94%20FINANCIAL%20INFORMATION) Presents the company's unaudited condensed consolidated financial statements and management's discussion and analysis of financial condition and results of operations [Item 1. Financial statements](index=8&type=section&id=Item%201.%20Financial%20statements) This section presents the unaudited condensed consolidated financial statements for Avantor, Inc. and its subsidiaries, including balance sheets, statements of operations, comprehensive income or loss, stockholders' equity, and cash flows, along with detailed notes explaining the nature of operations, accounting policies, segment information, debt, and other financial instruments [Unaudited condensed consolidated balance sheets](index=9&type=section&id=Unaudited%20condensed%20consolidated%20balance%20sheets) Presents the company's financial position, including assets, liabilities, and equity, at specific reporting dates Balance Sheet Highlights | Metric | June 30, 2025 (in millions) | December 31, 2024 (in millions) | | :-------------------------- | :-------------------------- | :-------------------------- | | Total assets | $12,776.9 | $12,114.5 | | Total liabilities | $6,491.0 | $6,157.8 | | Total stockholders' equity | $6,285.9 | $5,956.7 | | Cash and cash equivalents | $449.4 | $261.9 | | Current portion of debt | $1,254.3 | $821.1 | [Unaudited condensed consolidated statements of operations](index=10&type=section&id=Unaudited%20condensed%20consolidated%20statements%20of%20operations) Details the company's revenues, expenses, and net income or loss over specific periods Statements of Operations Highlights | Metric | Three months ended June 30, 2025 (in millions) | Three months ended June 30, 2024 (in millions) | Six months ended June 30, 2025 (in millions) | Six months ended June 30, 2024 (in millions) | | :-------------------------- | :--------------------------------------------- | :--------------------------------------------- | :------------------------------------------ | :------------------------------------------ | | Net sales | $1,683.4 | $1,702.8 | $3,264.8 | $3,382.6 | | Net income | $64.7 | $92.9 | $129.2 | $153.3 | | Basic EPS | $0.09 | $0.14 | $0.19 | $0.23 | | Diluted EPS | $0.09 | $0.14 | $0.19 | $0.22 | [Unaudited condensed consolidated statements of comprehensive income or loss](index=11&type=section&id=Unaudited%20condensed%20consolidated%20statements%20of%20comprehensive%20income%20or%20loss) Reports net income and other comprehensive income or loss components, reflecting total changes in equity from non-owner sources Comprehensive Income Highlights | Metric | Three months ended June 30, 2025 (in millions) | Three months ended June 30, 2024 (in millions) | Six months ended June 30, 2025 (in millions) | Six months ended June 30, 2024 (in millions) | | :-------------------- | :--------------------------------------------- | :--------------------------------------------- | :------------------------------------------ | :------------------------------------------ | | Net income | $64.7 | $92.9 | $129.2 | $153.3 | | Other comprehensive income (loss) | $107.3 | $(10.3) | $173.6 | $(38.3) | | Comprehensive income | $172.0 | $82.6 | $302.8 | $115.0 | - Comprehensive income significantly **increased** for both the three and six months ended June 30, 2025, primarily driven by unrealized gains from foreign currency translation[19](index=19&type=chunk) [Unaudited condensed consolidated statements of stockholders' equity](index=12&type=section&id=Unaudited%20condensed%20consolidated%20statements%20of%20stockholders'%20equity) Outlines changes in the company's equity accounts, including retained earnings and accumulated other comprehensive income Stockholders' Equity Highlights | Metric | Balance at Dec 31, 2024 (in millions) | Balance at Jun 30, 2025 (in millions) | | :-------------------------- | :------------------------------------ | :------------------------------------ | | Total stockholders' equity | $5,956.7 | $6,285.9 | | Accumulated earnings | $2,203.0 | $2,332.2 | | Accumulated other comprehensive loss | $(184.0) | $(10.4) | - Total stockholders' equity **increased** by **$329.2 million** from December 31, 2024, to June 30, 2025, largely due to comprehensive income and stock-based compensation[23](index=23&type=chunk) [Unaudited condensed consolidated statements of cash flows](index=14&type=section&id=Unaudited%20condensed%20consolidated%20statements%20of%20cash%20flows) Summarizes cash inflows and outflows from operating, investing, and financing activities over specific periods Cash Flow Summary | Cash Flow Activity | Six months ended June 30, 2025 (in millions) | Six months ended June 30, 2024 (in millions) | | :-------------------------------- | :------------------------------------------- | :------------------------------------------- | | Net cash provided by operating activities | $263.7 | $422.7 | | Net cash used in investing activities | $(57.5) | $(79.1) | | Net cash used in financing activities | $(40.5) | $(327.3) | | Net change in cash, cash equivalents and restricted cash | $187.5 | $9.0 | - Net cash provided by operating activities **decreased** by **$159.0 million** YoY, while net cash used in investing activities **improved** by **$21.6 million** due to lower capital expenditures. Net cash used in financing activities significantly **decreased** by **$286.8 million**, primarily due to the absence of term loan prepayments[25](index=25&type=chunk)[157](index=157&type=chunk)[158](index=158&type=chunk) [Notes to unaudited condensed consolidated financial statements](index=15&type=section&id=Notes%20to%20unaudited%20condensed%20consolidated%20financial%20statements) This section provides detailed explanations and disclosures for the unaudited condensed consolidated financial statements, covering the company's operations, new accounting standards, earnings per share calculations, segment performance, cash flow details, inventory, intangible assets, commitments, debt structure, accumulated other comprehensive income, stock-based compensation, other income/expense, income taxes, derivative and hedging activities, and fair value measurements of financial instruments [1. Nature of operations and presentation of financial statements](index=15&type=section&id=1.%20Nature%20of%20operations%20and%20presentation%20of%20financial%20statements) Describes the company's business activities and the basis for preparing its unaudited condensed consolidated financial statements - Avantor, Inc. is a global manufacturer and distributor serving biopharmaceutical, healthcare, education & government, and advanced technologies & applied materials industries[26](index=26&type=chunk) - The unaudited condensed consolidated financial statements are prepared pursuant to SEC regulations, reflecting normal, recurring adjustments, and are not necessarily indicative of full-year results[27](index=27&type=chunk) [2. New accounting standards](index=15&type=section&id=2.%20New%20accounting%20standards) Discusses recently issued accounting pronouncements and their potential impact on the company's financial reporting - ASU 2023-09 (Improvements to Income Tax Disclosures) is effective for annual periods beginning after December 15, 2024, and will result in additional disclosures for the year ending December 31, 2025[31](index=31&type=chunk)[32](index=32&type=chunk) - ASU 2024-03 (Disaggregation of Income Statement Expenses) is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027; the company is currently evaluating its impact[33](index=33&type=chunk)[34](index=34&type=chunk) [3. Earnings per share](index=16&type=section&id=3.%20Earnings%20per%20share) Provides details on basic and diluted earnings per share calculations for the reporting periods Earnings Per Share Data | Metric | Three months ended June 30, 2025 | Three months ended June 30, 2024 | Six months ended June 30, 2025 | Six months ended June 30, 2024 | | :-------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Basic EPS | $0.09 | $0.14 | $0.19 | $0.23 | | Diluted EPS | $0.09 | $0.14 | $0.19 | $0.22 | | Basic weighted average shares outstanding (millions) | 681.5 | 679.4 | 681.3 | 678.7 | | Diluted weighted average shares outstanding (millions) | 681.8 | 682.6 | 682.0 | 681.9 | - Anti-dilutive shares not included in diluted EPS were **16.7 million** for the three months and **14.7 million** for the six months ended June 30, 2025[36](index=36&type=chunk) [4. Segment financial information](index=17&type=section&id=4.%20Segment%20financial%20information) Presents financial data for the company's operating segments, including net sales and adjusted operating income - The company's reporting structure consists of two segments: Laboratory Solutions and Bioscience Production, with Adjusted Operating Income used to evaluate segment profitability[37](index=37&type=chunk)[38](index=38&type=chunk) Segment Performance Data | Segment | Period | Net Sales (2025, in millions) | Net Sales (2024, in millions) | Change (YoY) | Adjusted Operating Income (2025, in millions) | Adjusted Operating Income (2024, in millions) | Change (YoY) | | :-------------------- | :-------------------- | :---------------------------- | :---------------------------- | :----------- | :-------------------------------------------- | :-------------------------------------------- | :----------- | | Laboratory Solutions | Three months ended Jun 30 | $1,122.1 | $1,155.7 | (2.9%) | $133.3 | $150.9 | (11.7%) | | Bioscience Production | Three months ended Jun 30 | $561.3 | $547.1 | 2.6% | $139.7 | $144.0 | (3.0%) | | Total | Three months ended Jun 30 | $1,683.4 | $1,702.8 | (1.1%) | $252.2 | $277.2 | (9.0%) | | Laboratory Solutions | Six months ended Jun 30 | $2,187.1 | $2,312.8 | (5.4%) | $272.3 | $299.1 | (9.0%) | | Bioscience Production | Six months ended Jun 30 | $1,077.7 | $1,069.8 | 0.7% | $263.1 | $270.9 | (2.9%) | | Total | Six months ended Jun 30 | $3,264.8 | $3,382.6 | (3.5%) | $495.0 | $535.6 | (7.6%) | Product Category Data | Product Category | Period | 2025 (in millions) | 2024 (in millions) | | :--------------- | :-------------------- | :----------------- | :----------------- | | Proprietary | Three months ended Jun 30 | $893.8 | $914.0 | | Third-party | Three months ended Jun 30 | $789.6 | $788.8 | | Total | Three months ended Jun 30 | $1,683.4 | $1,702.8 | | Proprietary | Six months ended Jun 30 | $1,723.5 | $1,797.5 | | Third-party | Six months ended Jun 30 | $1,541.3 | $1,585.1 | | Total | Six months ended Jun 30 | $3,264.8 | $3,382.6 | [5. Supplemental disclosures of cash flow information](index=20&type=section&id=5.%20Supplemental%20disclosures%20of%20cash%20flow%20information) Offers additional details on cash and restricted cash balances and non-cash investing and financing activities Cash and Restricted Cash Balances | Metric | June 30, 2025 (in millions) | December 31, 2024 (in millions) | | :-------------------------- | :-------------------------- | :-------------------------- | | Cash and cash equivalents | $449.4 | $261.9 | | Restricted cash | $2.8 | $2.8 | | Total cash, cash equivalents and restricted cash | $452.2 | $264.7 | Cash Paid For | Cash Paid For | Six months ended June 30, 2025 (in millions) | Six months ended June 30, 2024 (in millions) | | :-------------------------- | :------------------------------------------- | :------------------------------------------- | | Income taxes, net | $93.8 | $86.5 | | Interest, net (excluding financing leases) | $79.3 | $116.1 | [6. Inventory](index=20&type=section&id=6.%20Inventory) Details the composition and changes in the company's inventory balances Inventory Composition | Inventory Component | June 30, 2025 (in millions) | December 31, 2024 (in millions) | | :------------------ | :-------------------------- | :-------------------------- | | Merchandise inventory | $451.6 | $416.0 | | Finished goods | $114.4 | $101.2 | | Raw materials | $150.1 | $149.3 | | Work in process | $63.7 | $65.0 | | Total | $779.8 | $731.5 | - Total inventory **increased** by **$48.3 million** from December 31, 2024, to June 30, 2025[16](index=16&type=chunk)[48](index=48&type=chunk) [7. Other intangible assets](index=21&type=section&id=7.%20Other%20intangible%20assets) Provides information on the carrying values and impairment of the company's finite-lived and indefinite-lived intangible assets Intangible Assets Carrying Values | Intangible Asset | June 30, 2025 (Carrying Value, in millions) | December 31, 2024 (Carrying Value, in millions) | | :--------------------- | :------------------------------------------ | :------------------------------------------ | | Customer relationships | $2,871.1 | $2,857.1 | | Trade names | $103.5 | $111.2 | | Other | $283.3 | $299.6 | | Total finite-lived | $3,257.9 | $3,267.9 | | Indefinite-lived | $92.3 | $92.3 | | Total | $3,350.2 | $3,360.2 | - Accumulated impairment losses on Customer relationships and Other intangible assets totaled **$106.4 million** as of June 30, 2025[50](index=50&type=chunk) [8. Commitments and contingencies](index=21&type=section&id=8.%20Commitments%20and%20contingencies) Discloses the company's environmental liabilities, legal proceedings, and other potential obligations - The company has an accrued obligation of **$2.3 million** for groundwater remediation in Phillipsburg, New Jersey, which is indemnified[52](index=52&type=chunk) - A liability of **$1.1 million** is recorded for soil and groundwater contamination remediation and monitoring at a site in Gliwice, Poland, which is not covered by indemnification[53](index=53&type=chunk) - As of June 30, 2025, there was no outstanding litigation believed to result in material losses[58](index=58&type=chunk) [9. Debt](index=23&type=section&id=9.%20Debt) Outlines the company's debt structure, including outstanding balances, interest rates, and credit facilities Debt Structure and Facilities | Debt Instrument | June 30, 2025 (Amount, in millions) | December 31, 2024 (Amount, in millions) | | :-------------------------- | :---------------------------------- | :---------------------------------- | | Total debt, gross | $4,261.0 | $4,077.8 | | Current portion of debt | $1,254.3 | $821.1 | | Debt, net of current portion | $2,988.2 | $3,234.7 | - Interest expense, net, for the six months ended June 30, 2025, was **$(85.6) million**, an **improvement** from **$(125.2) million** in 2024, primarily due to debt repayments[17](index=17&type=chunk)[60](index=60&type=chunk) - The U.S. Dollar term loan interest rate was repriced from SOFR plus **2.25%** to SOFR plus **2.00%** per annum on April 2, 2024[64](index=64&type=chunk) Credit Facility Details | Credit Facility | Capacity (in millions) | Undrawn letters of credit outstanding (in millions) | Outstanding borrowings (in millions) | Unused availability (in millions) | | :-------------------- | :--------------------- | :---------------------------------------- | :--------------------------------- | :-------------------------------- | | Receivables facility | $272.8 | $(15.0) | $(100.0) | $157.8 | | Revolving credit facility | $975.0 | $(3.4) | $0.0 | $971.6 | | Total | $1,247.8 | $(18.4) | $(100.0) | $1,129.4 | [10. Accumulated other comprehensive income (loss)](index=26&type=section&id=10.%20Accumulated%20other%20comprehensive%20income%20(loss)) Details the components and changes in accumulated other comprehensive income or loss Accumulated Other Comprehensive Income (Loss) Components | Component | Balance at Dec 31, 2024 (in millions) | Balance at Jun 30, 2025 (in millions) | | :-------------------------- | :------------------------------------ | :------------------------------------ | | Foreign currency translation | $(177.4) | $(23.8) | | Derivative instruments | $0.2 | $0.1 | | Defined benefit plans | $(6.8) | $13.3 | | Total AOCI | $(184.0) | $(10.4) | - AOCI **improved** significantly from a loss of **$184.0 million** at December 31, 2024, to a loss of **$10.4 million** at June 30, 2025, primarily due to unrealized gains from foreign currency translation[16](index=16&type=chunk)[67](index=67&type=chunk) [11. Stock-based compensation](index=27&type=section&id=11.%20Stock-based%20compensation) Provides information on stock-based compensation expense, unvested awards, and grants Stock-Based Compensation Expense | Compensation Type | Three months ended June 30, 2025 (in millions) | Three months ended June 30, 2024 (in millions) | Six months ended June 30, 2025 (in millions) | Six months ended June 30, 2024 (in millions) | | :-------------------- | :--------------------------------------------- | :--------------------------------------------- | :------------------------------------------ | :------------------------------------------ | | Stock options | $2.4 | $2.6 | $4.8 | $5.7 | | RSUs | $13.1 | $8.8 | $23.4 | $17.6 | | Other | $0.0 | $(0.3) | $(0.3) | $0.5 | | Total | $15.5 | $11.1 | $27.9 | $23.8 | - Unvested awards have a remaining expense of **$114.9 million** to be recognized over a weighted average period of **1.7 years** as of June 30, 2025[69](index=69&type=chunk) - During the six months ended June 30, 2025, the company granted **0.9 million** stock options and **4.4 million** RSUs[70](index=70&type=chunk)[71](index=71&type=chunk) [12. Other income or expense, net](index=28&type=section&id=12.%20Other%20income%20or%20expense,%20net) Reports non-operating income and expenses, including foreign currency impacts and pension-related charges Other Income/Expense Breakdown | Component | Three months ended June 30, 2025 (in millions) | Three months ended June 30, 2024 (in millions) | Six months ended June 30, 2025 (in millions) | Six months ended June 30, 2024 (in millions) | | :------------------------------------------ | :--------------------------------------------- | :--------------------------------------------- | :------------------------------------------ | :------------------------------------------ | | Net foreign currency (loss) gain from financing activities | $(3.9) | $1.0 | $(7.1) | $1.8 | | (Expense) income related to defined benefit plans | $(0.3) | $0.6 | $(17.8) | $0.9 | | Other (expense) income, net | $(3.7) | $1.6 | $(23.2) | $2.7 | - Other (expense) income, net, for the six months ended June 30, 2025, was a **$(23.2) million** expense, primarily due to **$18.1 million** in pension termination costs recorded in the first quarter of 2025[72](index=72&type=chunk)[74](index=74&type=chunk) [13. Income taxes](index=29&type=section&id=13.%20Income%20taxes) Details income before taxes, income tax expense, and the effective income tax rate, along with recent tax law changes Income Tax Metrics | Metric | Three months ended June 30, 2025 | Three months ended June 30, 2024 | Six months ended June 30, 2025 | Six months ended June 30, 2024 | | :-------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Income before income taxes | $81.7 | $114.6 | $167.4 | $195.2 | | Income tax expense | $(17.0) | $(21.7) | $(38.2) | $(41.9) | | Effective income tax rate | **20.8%** | **18.9%** | **22.8%** | **21.5%** | - The change in the effective tax rate for the three and six months ended June 30, 2025, is primarily due to a year-to-date shortfall in the tax deduction from stock option exercises[78](index=78&type=chunk) - The U.S. enacted H.R. 1 (One Big Beautiful Bill Act) on July 4, 2025, which is anticipated to reduce current and ongoing cash tax obligations due to provisions like immediate expensing for R&D and **100%** bonus depreciation[79](index=79&type=chunk) [14. Derivative and hedging activities](index=29&type=section&id=14.%20Derivative%20and%20hedging%20activities) Describes the company's use of interest rate and cross-currency swaps to manage financial risks - The company uses interest rate swaps as cash flow hedges to manage interest rate risk, with an immaterial amount estimated to be reclassified as an **increase** to interest expense in the next twelve months[82](index=82&type=chunk)[83](index=83&type=chunk) - Cross-currency swaps are used to hedge net investments in foreign entities, with a total notional amount of **$750.0 million** at June 30, 2025, maturing in April 2027, 2028, and 2029[90](index=90&type=chunk)[91](index=91&type=chunk) - A **€400.0 million** senior unsecured note previously designated as a net investment hedge was de-designated in October 2024, with no impact on earnings[95](index=95&type=chunk)[96](index=96&type=chunk) [15. Financial instruments and fair value measurements](index=33&type=section&id=15.%20Financial%20instruments%20and%20fair%20value%20measurements) Presents the fair value measurements of the company's financial instruments, particularly debt Fair Value of Debt Instruments | Debt Instrument | June 30, 2025 (Gross Amount, in millions) | June 30, 2025 (Fair Value, in millions) | | :-------------------------- | :---------------------------------------- | :-------------------------------------- | | Receivables facility | $100.0 | $100.0 | | Senior secured credit facilities | $538.5 | $540.1 | | Secured notes | $763.9 | $763.6 | | Unsecured notes | $2,820.1 | $2,750.8 | | Finance lease liabilities | $29.9 | $29.9 | | Other | $8.6 | $8.6 | | Total | $4,261.0 | $4,193.0 | - The fair values of debt instruments are based on standard pricing models and private trading data, classified as Level 2 measurements[102](index=102&type=chunk) [Item 2. Management's discussion and analysis of financial condition and results of operations](index=34&type=section&id=Item%202.%20Management's%20discussion%20and%20analysis%20of%20financial%20condition%20and%20results%20of%20operations) This section provides management's perspective on Avantor's financial condition and results of operations for the quarter and six months ended June 30, 2025. It discusses key financial performance indicators, factors influencing the business, and a detailed analysis of net sales, gross margin, operating income, net income, and non-GAAP measures like Adjusted EBITDA and Adjusted Operating Income, concluding with an overview of liquidity and capital resources [Basis of presentation](index=34&type=section&id=Basis%20of%20presentation) Explains the context for management's discussion and analysis, emphasizing material changes since the last annual report - This discussion should be read in conjunction with the unaudited condensed consolidated financial statements and notes, focusing on material changes since December 31, 2024[103](index=103&type=chunk) [Overview](index=34&type=section&id=Overview) Summarizes the company's key financial performance indicators for the reporting period, including net sales and net income Quarterly Performance Overview | Metric | Three months ended June 30, 2025 (in millions) | | :-------------------------- | :--------------------------------------------- | | Net sales | $1,683.4 | | Net income | $64.7 | | Adjusted EBITDA | $279.8 | | Adjusted Operating Income | $252.2 | - Net sales for Q2 2025 **declined 1.1%**, including a **0.2%** organic net sales **decrease** compared to Q2 2024[104](index=104&type=chunk) [Factors and current trends affecting our business and results of operations](index=35&type=section&id=Factors%20and%20current%20trends%20affecting%20our%20business%20and%20results%20of%20operations) Discusses significant internal and external factors influencing the company's financial performance and strategic direction - The sale of the Clinical Services business on October 17, 2024, impacts results but was not classified as a discontinued operation[106](index=106&type=chunk) - The company continues to experience inflationary pressures across all cost categories, which may adversely impact results despite mitigation efforts[107](index=107&type=chunk) - The global cost transformation initiative has expanded, now targeting approximately **$400 million** in run rate gross savings by the end of 2027, up from the previous target of **$300 million** by the end of 2026[109](index=109&type=chunk)[110](index=110&type=chunk) - Fluctuations in foreign currency rates, particularly the Euro, have caused significant variability in consolidated results[111](index=111&type=chunk) [Key indicators of performance and financial condition](index=36&type=section&id=Key%20indicators%20of%20performance%20and%20financial%20condition) Identifies the primary GAAP and non-GAAP metrics used by management to assess the company's operational and financial health - The company monitors GAAP measures (Net sales, gross margin, operating income, net income) and non-GAAP measures (Organic net sales growth, Adjusted EBITDA, Adjusted Operating Income, Free cash flow) to evaluate performance[114](index=114&type=chunk)[117](index=117&type=chunk) - Organic net sales growth (decline) is a non-GAAP measure that eliminates impacts from acquisitions, divestitures, and foreign currency exchange rates to assess underlying commercial operating performance[114](index=114&type=chunk) - Adjusted EBITDA and Adjusted Operating Income are non-GAAP measures used to analyze underlying business trends and segment profitability, respectively[114](index=114&type=chunk) [Results of operations](index=37&type=section&id=Results%20of%20operations) This section details the financial performance for the three and six months ended June 30, 2025, highlighting declines in net sales, gross margin, operating income, and net income, primarily due to reduced customer demand, the Clinical Services divestiture, and inflationary pressures, partially offset by cost transformation savings. It also provides segment-specific performance for Laboratory Solutions and Bioscience Production [Executive summary](index=37&type=section&id=Executive%20summary) Provides a high-level overview of the company's financial results, highlighting key changes in sales, margins, and profitability Executive Summary Financials | Metric | Three months ended June 30, 2025 | Three months ended June 30, 2024 | Change | | :-------------------------- | :------------------------------- | :------------------------------- | :------- | | Net sales | $1,683.4M | $1,702.8M | $(19.4)M | | Gross margin | **32.9%** | **34.1%** | **(120) bps** | | Operating income | $128.8M | $175.8M | $(47.0)M | | Net income | $64.7M | $92.9M | $(28.2)M | | Adjusted EBITDA | $279.8M | $305.6M | $(25.8)M | | Adjusted Operating Income | $252.2M | $277.2M | $(25.0)M | - The Q2 net sales **decline** was primarily driven by reduced customer demand in the Laboratory Solutions segment and the divestiture of the Clinical Services business[116](index=116&type=chunk) - Lower gross profit, partially offset by savings from the cost transformation initiative, resulted in lower Adjusted Operating Income and Adjusted EBITDA[116](index=116&type=chunk) [Net Sales](index=38&type=section&id=Net%20Sales) Analyzes the drivers of net sales performance, including organic growth, foreign currency impacts, and divestitures, across segments Net Sales Growth by Segment | Segment | Period | Net sales growth (decline) | Foreign currency impact | Divestiture impact | Organic net sales growth (decline) | | :-------------------- | :-------------------- | :------------------------- | :---------------------- | :----------------- | :--------------------------------- | | Laboratory Solutions | Three months ended Jun 30 | $(33.6)M | $25.6M | $(48.1)M | $(11.1)M | | Bioscience Production | Three months ended Jun 30 | $14.2M | $5.8M | $0.0M | $8.4M | | Total | Three months ended Jun 30 | $(19.4)M | $31.4M | $(48.1)M | $(2.7)M | | Laboratory Solutions | Six months ended Jun 30 | $(125.7)M | $11.1M | $(92.2)M | $(44.6)M | | Bioscience Production | Six months ended Jun 30 | $7.9M | $1.3M | $0.0M | $6.6M | | Total | Six months ended Jun 30 | $(117.8)M | $12.4M | $(92.2)M | $(38.0)M | - Laboratory Solutions organic net sales **decreased** due to lower demand for consumables in Total Science Solutions, while Bioscience Production organic net sales **increased** due to higher sales volume in Silicones and **improved** sales of process ingredients and excipients[119](index=119&type=chunk)[120](index=120&type=chunk)[122](index=122&type=chunk)[123](index=123&type=chunk) [Gross margin](index=39&type=section&id=Gross%20margin) Examines the factors influencing the company's gross margin, such as pricing, costs, and product mix Gross Margin Trends | Metric | Three months ended June 30, 2025 | Three months ended June 30, 2024 | Change | Six months ended June 30, 2025 | Six months ended June 30, 2024 | Change | | :----------- | :------------------------------- | :------------------------------- | :----- | :----------------------------- | :----------------------------- | :----- | | Gross margin | **32.9%** | **34.1%** | **(120) bps** | **33.4%** | **34.1%** | **(70) bps** | - Gross margin **contracted** due to inflationary pressures, the divestiture of the Clinical Services business, and unfavorable manufacturing variances[125](index=125&type=chunk) [Operating income](index=39&type=section&id=Operating%20income) Details the components affecting operating income, including gross profit, operating expenses, and strategic initiatives Operating Income Breakdown | Metric | Three months ended June 30, 2025 (in millions) | Three months ended June 30, 2024 (in millions) | Change (in millions) | Six months ended June 30, 2025 (in millions) | Six months ended June 30, 2024 (in millions) | Change (in millions) | | :--------------- | :--------------------------------------------- | :--------------------------------------------- | :------------------- | :------------------------------------------ | :------------------------------------------ | :------------------- | | Gross profit | $554.1 | $581.5 | $(27.4) | $1,089.0 | $1,152.0 | $(63.0) | | Operating expenses | $425.3 | $405.7 | $19.6 | $812.8 | $829.9 | $(17.1) | | Operating income | $128.8 | $175.8 | $(47.0) | $276.2 | $322.1 | $(45.9) | - Operating income **decreased** primarily due to lower gross profit and higher SG&A expenses (driven by restructuring, transformation expenses, and inflationary compensation), partially offset by cost transformation savings and the Clinical Services divestiture[127](index=127&type=chunk)[128](index=128&type=chunk) [Net income](index=40&type=section&id=Net%20income) Explains the changes in net income, considering operating performance, interest expense, and other non-operating items Net Income Trends | Metric | Three months ended June 30, 2025 (in millions) | Three months ended June 30, 2024 (in millions) | Change (in millions) | Six months ended June 30, 2025 (in millions) | Six months ended June 30, 2024 (in millions) | Change (in millions) | | :-------------------------- | :--------------------------------------------- | :--------------------------------------------- | :------------------- | :------------------------------------------ | :------------------------------------------ | :------------------- | | Operating income | $128.8 | $175.8 | $(47.0) | $276.2 | $322.1 | $(45.9) | | Net income | $64.7 | $92.9 | $(28.2) | $129.2 | $153.3 | $(24.1) | - Net income **decreased** primarily due to lower operating income and pension termination charges, partially offset by lower interest expense resulting from debt repayments[130](index=130&type=chunk)[131](index=131&type=chunk) [Adjusted EBITDA and Adjusted EBITDA margin](index=40&type=section&id=Adjusted%20EBITDA%20and%20Adjusted%20EBITDA%20margin) Discusses the company's non-GAAP Adjusted EBITDA and its margin, highlighting adjustments for non-recurring items Adjusted EBITDA and Margin | Metric | Three months ended June 30, 2025 (in millions) | Three months ended June 30, 2024 (in millions) | Change (in millions) | Six months ended June 30, 2025 (in millions) | Six months ended June 30, 2024 (in millions) | Change (in millions) | | :-------------------- | :--------------------------------------------- | :--------------------------------------------- | :------------------- | :------------------------------------------ | :------------------------------------------ | :------------------- | | Adjusted EBITDA | $279.8 | $305.6 | $(25.8) | $549.3 | $588.6 | $(39.3) | | Adjusted EBITDA margin | **16.6%** | **17.9%** | **(130) bps** | **16.8%** | **17.4%** | **(60) bps** | - The **decline** in Adjusted EBITDA was primarily driven by the divestiture of the Clinical Services business, lower gross profit, and inflationary pressures on compensation expense, partially offset by savings from the cost transformation initiative[133](index=133&type=chunk)[134](index=134&type=chunk) [Adjusted Operating Income and Adjusted Operating Income margin](index=41&type=section&id=Adjusted%20Operating%20Income%20and%20Adjusted%20Operating%20Income%20margin) Analyzes segment-level profitability using non-GAAP Adjusted Operating Income and its margin Adjusted Operating Income by Segment | Segment | Period | Adjusted Operating Income (2025, in millions) | Adjusted Operating Income (2024, in millions) | Change (in millions) | | :-------------------- | :-------------------- | :-------------------------------------------- | :-------------------------------------------- | :------------------- | | Laboratory Solutions | Three months ended Jun 30 | $133.3 | $150.9 | $(17.6) | | Bioscience Production | Three months ended Jun 30 | $139.7 | $144.0 | $(4.3) | | Corporate | Three months ended Jun 30 | $(20.8) | $(17.7) | $(3.1) | | Total | Three months ended Jun 30 | $252.2 | $277.2 | $(25.0) | | Adjusted Operating Income margin | Three months ended Jun 30 | **15.0%** | **16.3%** | **(130) bps** | - Laboratory Solutions Adjusted Operating Income **declined** due to the Clinical Services divestiture, inflationary pressures, and unfavorable product mix, while Bioscience Production **declined** due to unfavorable manufacturing variances and inflationary compensation[137](index=137&type=chunk)[138](index=138&type=chunk)[140](index=140&type=chunk)[141](index=141&type=chunk)[142](index=142&type=chunk) Adjusted Operating Income by Segment (Six Months) | Segment | Period | Adjusted Operating Income (2025, in millions) | Adjusted Operating Income (2024, in millions) | Change (in millions) | | :-------------------- | :-------------------- | :-------------------------------------------- | :-------------------------------------------- | :------------------- | | Laboratory Solutions | Six months ended Jun 30 | $272.3 | $299.1 | $(26.8) | | Bioscience Production | Six months ended Jun 30 | $263.1 | $270.9 | $(7.8) | | Corporate | Six months ended Jun 30 | $(40.4) | $(34.4) | $(6.0) | | Total | Six months ended Jun 30 | $495.0 | $535.6 | $(40.6) | | Adjusted Operating Income margin | Six months ended Jun 30 | **15.2%** | **15.8%** | **(60) bps** | [Reconciliations of non-GAAP measures](index=43&type=section&id=Reconciliations%20of%20non-GAAP%20measures) Provides detailed reconciliations from GAAP net income to non-GAAP financial measures like Adjusted EBITDA and Adjusted Operating Income Non-GAAP Adjustments | Adjustment | Three months ended June 30, 2025 (in millions) | Six months ended June 30, 2025 (in millions) | | :-------------------------- | :--------------------------------------------- | :------------------------------------------ | | Restructuring and severance charges | $21.4 | $25.8 | | Transformation expenses | $20.4 | $35.8 | | Reserve for certain legal matters, net | $3.6 | $3.6 | | Pension termination charges | $0.0 | $18.1 | - The reconciliation tables provide detailed adjustments from GAAP net income to non-GAAP Adjusted EBITDA and Adjusted Operating Income, including items like amortization, restructuring, and transformation expenses[144](index=144&type=chunk)[148](index=148&type=chunk) [Liquidity and capital resources](index=44&type=section&id=Liquidity%20and%20capital%20resources) This section outlines Avantor's liquidity position, sources of funding, historical cash flow performance, and debt structure. It highlights a decrease in cash from operating activities but an improvement in cash used in investing and financing activities, resulting in lower free cash flow for the six months ended June 30, 2025 [Liquidity](index=45&type=section&id=Liquidity) Assesses the company's short-term financial health, including available cash and credit facilities Liquidity Position | Metric | June 30, 2025 (in millions) | | :-------------------------------- | :-------------------------- | | Unused availability under credit facilities | $1,129.4 | | Cash and cash equivalents | $449.4 | | Total liquidity | $1,578.8 | - The company has **$1,254.3 million** in current portion of debt due in the next twelve months[16](index=16&type=chunk)[151](index=151&type=chunk) - **$291.4 million** (**64.8%**) of cash and cash equivalents was held by non-U.S. subsidiaries, which may be subject to certain taxes upon repatriation[154](index=154&type=chunk) [Historical cash flows](index=46&type=section&id=Historical%20cash%20flows) Reviews the company's cash generation and usage from operating, investing, and financing activities over time Historical Cash Flow Activities | Cash Flow Activity | Six months ended June 30, 2025 (in millions) | Six months ended June 30, 2024 (in millions) | Change (in millions) | | :-------------------------------- | :------------------------------------------- | :------------------------------------------- | :------------------- | | Net cash provided by operating activities | $263.7 | $422.7 | $(159.0) | | Net cash used in investing activities | $(57.5) | $(79.1) | $21.6 | | Financing activities | $(40.5) | $(327.3) | $286.8 | - The **decrease** in operating cash flow was primarily due to higher net working capital requirements, higher incentive compensation payments, and lower income before income taxes[157](index=157&type=chunk) - The significant **decrease** in cash used in financing activities was primarily due to the absence of term loan prepayments in the current year[158](index=158&type=chunk) [Free cash flow](index=46&type=section&id=Free%20cash%20flow) Analyzes the company's ability to generate cash after capital expenditures, a key measure of financial flexibility Free Cash Flow Analysis | Metric | Six months ended June 30, 2025 (in millions) | Six months ended June 30, 2024 (in millions) | Change (in millions) | | :-------------------------- | :------------------------------------------- | :------------------------------------------- | :------------------- | | Net cash provided by operating activities | $263.7 | $422.7 | $(159.0) | | Capital expenditures | $(57.6) | $(80.5) | $22.9 | | Divestiture-related transaction expenses and taxes paid | $1.4 | $0.0 | $1.4 | | Free cash flow | $207.5 | $342.2 | $(134.7) | - Free cash flow **decreased** by **$134.7 million**, primarily due to lower cash flow from operating activities, partially offset by a **decrease** in capital expenditures[159](index=159&type=chunk) [Indebtedness](index=47&type=section&id=Indebtedness) Refers to detailed information on the company's debt structure and obligations - For detailed information about indebtedness, refer to Note 9 to the unaudited condensed consolidated financial statements[160](index=160&type=chunk) [Item 3. Quantitative and qualitative disclosures about market risk](index=47&type=section&id=Item%203.%20Quantitative%20and%20qualitative%20disclosures%20about%20market%20risk) States that there were no material changes to the company's market risk disclosures during the quarter ended June 30, 2025 - There were no material changes to the quantitative and qualitative disclosures about market risk during the quarter ended June 30, 2025, as reported in the Annual Report[160](index=160&type=chunk) [Item 4. Controls and procedures](index=47&type=section&id=Item%204.%20Controls%20and%20procedures) Confirms the effectiveness of the company's disclosure controls and internal control over financial reporting - Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were effective as of June 30, 2025[161](index=161&type=chunk) - No material changes in internal control over financial reporting occurred during the fiscal quarter ended June 30, 2025[162](index=162&type=chunk) [PART II — OTHER INFORMATION](index=47&type=section&id=PART%20II%20%E2%80%94%20OTHER%20INFORMATION) Contains disclosures on legal proceedings, risk factors, equity sales, defaults, mine safety, other information, and exhibits [Item 1. Legal proceedings](index=47&type=section&id=Item%201.%20Legal%20proceedings) Refers to Note 8 of the financial statements for information on legal proceedings, confirming no material outstanding litigation - For additional information regarding legal proceedings, refer to Note 8 of the unaudited condensed consolidated financial statements[163](index=163&type=chunk) - As of June 30, 2025, there was no outstanding litigation believed to result in material losses[58](index=58&type=chunk) [Item 1A. Risk factors](index=47&type=section&id=Item%201A.%20Risk%20factors) Confirms no material changes to previously disclosed risk factors - No material changes to the risk factors disclosed in the Annual Report for the year ended December 31, 2024, or the Quarterly Report on Form 10-Q for the period ended March 31, 2025, were reported[164](index=164&type=chunk) [Item 2. Unregistered sales of equity securities and use of proceeds](index=47&type=section&id=Item%202.%20Unregistered%20sales%20of%20equity%20securities%20and%20use%20of%20proceeds) States that no unregistered sales of equity securities or use of proceeds occurred during the period - None reported[165](index=165&type=chunk) [Item 3. Defaults upon senior securities](index=48&type=section&id=Item%203.%20Defaults%20upon%20senior%20securities) No defaults upon senior securities were reported during the period - None reported[166](index=166&type=chunk) [Item 4. Mine safety disclosures](index=48&type=section&id=Item%204.%20Mine%20safety%20disclosures) This item is not applicable to the company - Not applicable[167](index=167&type=chunk) [Item 5. Other information](index=48&type=section&id=Item%205.%20Other%20information) This section discloses that Michael Stubblefield, Director, President, and CEO, adopted a Rule 10b5-1 trading plan on May 6, 2025, to sell up to 906,204 shares through stock option exercises. No other directors or officers adopted or terminated such plans during the quarter - Michael Stubblefield, Director, President, and Chief Executive Officer, adopted a Rule 10b5-1 trading plan on May 6, 2025, to sell up to **906,204** shares through the exercise of stock options[168](index=168&type=chunk) - No other directors or officers adopted or terminated Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the three months ended June 30, 2025[169](index=169&type=chunk) [Item 6. Exhibits](index=49&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including transition agreements, severance plans, RSU grant notices, certifications, and XBRL exhibits - Exhibits include the Transition Agreement for Michael Stubblefield, the Avantor, Inc. Executive Severance and Change in Control Plan, Form of 2025 Restricted Stock Unit Grant Notice, and certifications required by the Sarbanes-Oxley Act[173](index=173&type=chunk) [Signature](index=50&type=section&id=Signature) Confirms the official signing and submission of the report

Financial Data and Key Metrics Changes - Organic revenue growth improved sequentially by 200 basis points and was flat year over year [6] - Adjusted EBITDA margin contracted to 16.6% [7] - Adjusted EPS for the quarter was $0.24, a decline of $0.01 year over year [18] - Free cash flow was $125 million with adjusted conversion at 100% [7][18] - Adjusted net leverage ended the quarter at 3.2 times adjusted EBITDA, unchanged from Q1 [18] Business Line Data and Key Metrics Changes - Laboratory Solutions revenue was $1,122 million, declining 1% year over year but growing 2% sequentially [19] - Bioscience production revenue was $561 million, up 2% organically year over year and up 7% sequentially [21] - Bioprocessing performance was flat year over year, impacted by customer headwinds and extended maintenance [12][21] Market Data and Key Metrics Changes - European business was nearly flat, outperforming The Americas and Asia, which faced greater policy headwinds [20] - Demand for core monoclonal antibody platform remains strong despite challenges faced by large customers [13][44] Company Strategy and Development Direction - The company remains focused on executing strategic initiatives to drive growth, improve operating efficiency, and deliver long-term value [6][30] - Significant contract extensions with top global pharma accounts are expected to result in over $100 million in share gains [11] - The company is committed to protecting and growing market share while preserving profitability [12] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing challenges in the operating environment but expressed confidence in the company's ability to expand margins over time [12][30] - The outlook for full-year organic revenue growth has been reduced to negative 2% to flat, reflecting current trends [23] - Management expects continued strong demand for the core monoclonal antibody platform despite headwinds [44] Other Important Information - A leadership transition was announced, with Emanuel Ligner appointed as the next CEO effective August 18 [5] - The company is on track with its cost transformation program, expecting $400 million in run rate savings by 2027 [7] Q&A Session Summary Question: What is the assumption for the segments in the third quarter guidance? - Management indicated that performance is expected to be consistent across segments, with some seasonality affecting results [34] Question: How much of the EBITDA margin decline was due to mix versus pricing? - The decline was primarily driven by pricing actions in the lab business, with some impact from underperformance in bioprocessing [36] Question: What are the expectations for bioprocessing growth long-term? - Management remains confident that bioprocessing can grow at mid to high single digits, despite recent challenges [46] Question: What actions are being taken to improve bioprocessing performance? - The team is focusing on optimizing supply chain, increasing field intensity, and expanding product offerings [14][93] Question: How are the recent contract extensions linked to share gains? - The extensions are expected to result in increased commitments from existing customers, contributing to share gains [105] Question: What is the outlook for margins in the lab business? - Management expects margins to improve as share gains materialize and operational efficiencies are realized [88]

Company Performance - Avantor, Inc. reported quarterly earnings of $0.24 per share, missing the Zacks Consensus Estimate of $0.25 per share, and down from $0.25 per share a year ago, representing an earnings surprise of -4.00% [1] - The company posted revenues of $1.68 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.38%, but down from year-ago revenues of $1.7 billion [2] - Over the last four quarters, Avantor has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Performance - Avantor shares have lost approximately 36.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.8% [3] - The current Zacks Rank for Avantor is 5 (Strong Sell), indicating expectations for the stock to underperform the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is $0.27 on revenues of $1.7 billion, and for the current fiscal year, it is $1.03 on revenues of $6.69 billion [7] - The outlook for the Medical Services industry, where Avantor operates, is currently in the top 35% of over 250 Zacks industries, suggesting potential for better performance compared to lower-ranked industries [8]

Q2 2025 Earnings Earnings Presentation August 1, 2025 Disclaimer Forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this presentation are forward-looking statements. Forward-looking s ...

Exhibit 99.1 Avantor® Reports Second Quarter 2025 Results RADNOR, Pa. – August 1, 2025 – Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2025. "In the second quarter, we remained focused on driving growth, enhancing operating leverage, and executing with discipline," said Michael Stubblefield, President and Chief E ...